The Medical Letter on Drugs and Therapeutics
Long-Acting Injectable Aripiprazole (Abilify Maintena) for Schizophrenia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

An extended-release injectable formulation of the second-generation antipsychotic aripiprazole (Abilify) has been approved by the FDA (Abilify Maintena – Otsuka/Lundbeck) for once-monthly treatment of schizophrenia. It is the fourth second-generation antipsychotic to become available in a long-acting parenteral formulation. Long-acting parenteral antipsychotics, given at intervals of 2-4 weeks, are generally used for patients with a history of relapse due to poor adherence to oral maintenance therapy.

DRUGS FOR SCHIZOPHRENIA — Second-generation antipsychotics are now used more commonly than first-generation drugs, but controlled trials have failed to demonstrate a clear advantage in efficacy with the newer drugs, except for clozapine and possibly olanzapine.1 The second-generation antipsychotics have a relatively low risk of extrapyramidal symptoms, and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Long-Acting Injectable Aripiprazole (Abilify Maintena) for Schizophrenia
Article code: 1415b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian